SHR-A1811 targets HER2 on the cell surface; after HER2-mediated uptake, it releases a camptothecin payload that inhibits topoisomerase I, causing DNA damage and apoptosis in HER2-positive cells (with possible bystander killing). Topoisomerase I itself is not the targeted antigen.